Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sinovac Biotech Ltd. (SVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Sinovac furnishes information to the U.S. Securities and Exchange Commission (SEC) primarily through Form 20‑F annual reports and Form 6‑K current reports, which include press releases, proxy materials, and other significant updates.
For a vaccine-focused biopharmaceutical company like Sinovac, annual reports on Form 20‑F and related filings are central sources for understanding its vaccine portfolio, risk factors, and financial condition. While the specific contents of Sinovac’s 20‑F filings are not reproduced here, the company has publicly discussed delays in filing its 2024 annual report and its engagement of independent auditors to complete multi-year audits and internal control assessments. These filings are directly relevant for investors tracking compliance with Nasdaq Listing Rules and SEC reporting requirements.
Sinovac’s Form 6‑K submissions frequently attach press releases covering topics such as special shareholder meetings, litigation outcomes in Antigua and other jurisdictions, proxy advisory recommendations, dividend payments, and board communications. For example, recent 6‑Ks have furnished press releases on the adjournment of a Special Meeting of Shareholders, court decisions related to PIPE shares, the status of a US$55.00 per common share special cash dividend, and the engagement of new independent auditors.
Through this page, users can review Sinovac’s historical and recent 6‑K filings to follow governance disputes, corporate actions, and listing status updates, alongside financial reporting milestones. Stock Titan’s interface is designed to surface new filings as they are made available from EDGAR and to pair them with AI-powered summaries that explain the purpose of each document in plain language, such as distinguishing between a current report on Form 6‑K and an annual report on Form 20‑F.
Investors researching Sinovac’s regulatory history can use this filings archive to examine how the company has communicated about auditor changes, Nasdaq notifications regarding late filings and delisting determinations, proxy contests, and dividend distributions, all of which are documented in its SEC submissions.
SINOVAC BIOTECH LTD executive Li Jing, VP of Quality and Production, has filed an initial insider ownership report. The filing shows direct ownership of 227,500 common shares, with no insider buy or sell transactions reported in this statement.
SINOVAC BIOTECH LTD executive Yang Guang (Helen), the Chief Business Officer, has filed an initial ownership report. The Form 3 shows she directly holds 172,900 common shares of the company. This filing records her existing stake as an insider and does not reflect a new purchase or sale.
SINOVAC BIOTECH LTD executive Gao Qiang, the Chief Operation Officer, has filed an initial ownership report showing direct holdings of 230,000 common shares. This Form 3 does not report any new purchase or sale, only the number of shares he beneficially owns after the reported holdings.
SINOVAC BIOTECH LTD Chief Financial Officer Wang Nan filed an initial ownership report showing holdings of 355,000 common shares. This Form 3 establishes Wang Nan’s existing direct ownership position in the company’s common equity and serves as a baseline for any future insider transactions.
SINOVAC BIOTECH LTD filed an initial insider ownership report for director WANG YU (NMN) on Form 3. This filing lists Wang as a director of the company but does not show any reported transactions or derivative positions in the provided data.
SINOVAC BIOTECH LTD director Jiao Shuge has filed an initial ownership report on Form 3. This filing identifies him as a director of the company and establishes his status as an insider. The filing does not report any share purchases, sales, or other transactions.
SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3. The filing reports direct ownership of 90,000 common shares, par value $0.001 per share. This is a holdings report only and does not reflect any recent share purchase or sale.
SINOVAC BIOTECH LTD director Qiu Yu Min filed an initial Form 3, which is a required disclosure of insider status. This filing reports no transactions in the company’s securities and no derivative holdings, serving only to register Qiu Yu Min as a reporting insider.
SINOVAC BIOTECH LTD director Fu Shan filed an initial ownership report showing indirect holdings of 5,903,000 common shares. These shares are held by Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P., for which entities he serves as managing member of the general partners and may share voting and dispositive power with other members. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
SINOVAC BIOTECH LTD